skip to the content

Clinical Trials

SLE - Pediatric Atherosclerosis Prevention Study

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Effectiveness of Lipitor (atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE:  The Atherosclerosis Prevention in Pediatric

Protocol ID

03.10.074T

Protocol Description

People with systemic lupus erythematosus (SLE) are at high risk for developing atherosclerosis. We are doing this study to find out whether or not a drug called atorvastatin, also known as Lipitor, will lower lipid levels, decrease inflammation and lessen heart, stroke and circulatory problems in people from age 10 through 21 years with SLE. We are also studying the outcome of lupus.

Eligibility Criteria

Patients with systemic lupus erythematosus (SLE)

Primary Investigator(s)

  • Anne Eberhard, MD

Contact Information

Marlyn Orlando, RN
(718) 470-3232
morlando@lij.edu

Last Update

April 2, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Lupus:
top
top